SG11201400499PA - Sall4 and uses thereof - Google Patents

Sall4 and uses thereof

Info

Publication number
SG11201400499PA
SG11201400499PA SG11201400499PA SG11201400499PA SG11201400499PA SG 11201400499P A SG11201400499P A SG 11201400499PA SG 11201400499P A SG11201400499P A SG 11201400499PA SG 11201400499P A SG11201400499P A SG 11201400499PA SG 11201400499P A SG11201400499P A SG 11201400499PA
Authority
SG
Singapore
Prior art keywords
sall4
Prior art date
Application number
SG11201400499PA
Inventor
Li Chai
Todor Dimitrov
Daniel Geoffrey Tenen
Kol Jia Yong
Original Assignee
Brigham & Womens Hospital
Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Univ Singapore filed Critical Brigham & Womens Hospital
Publication of SG11201400499PA publication Critical patent/SG11201400499PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
SG11201400499PA 2011-09-20 2012-09-20 Sall4 and uses thereof SG11201400499PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161536940P 2011-09-20 2011-09-20
PCT/SG2012/000347 WO2013043128A1 (en) 2011-09-20 2012-09-20 Sall4 and uses thereof

Publications (1)

Publication Number Publication Date
SG11201400499PA true SG11201400499PA (en) 2014-06-27

Family

ID=47914684

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201602149XA SG10201602149XA (en) 2011-09-20 2012-09-20 SALL4 And Uses Thereof
SG11201400499PA SG11201400499PA (en) 2011-09-20 2012-09-20 Sall4 and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201602149XA SG10201602149XA (en) 2011-09-20 2012-09-20 SALL4 And Uses Thereof

Country Status (4)

Country Link
US (1) US9365851B2 (en)
CN (1) CN103945860A (en)
SG (2) SG10201602149XA (en)
WO (1) WO2013043128A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105087796A (en) * 2015-08-17 2015-11-25 中南大学湘雅三医院 Application of gene Sall4 to preparation of intrahepatic cholangiocarcinoma (ICC) prognosis preparations
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US10793601B2 (en) 2016-04-28 2020-10-06 National University Of Singapore Therapeutic spalt-like transcription factor 4 (SALL4) peptide
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
EP3692052A4 (en) 2017-10-04 2021-03-17 Dana Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor sall4 and uses thereof
CN108660148A (en) * 2018-05-29 2018-10-16 奇元科技（武汉）有限公司 A kind of method and its application for expressing external source drug based on genetic modification probiotics
CN109666064B (en) * 2018-12-29 2022-04-05 上海锐赛生物技术有限公司 SALL4-RBBp4 compound blocking polypeptide and derivative antitumor polypeptide and application thereof
WO2020242376A1 (en) * 2019-05-28 2020-12-03 Agency For Science, Technology And Research Method of treating a sall4-expressing cancer
WO2021041861A1 (en) * 2019-08-30 2021-03-04 National University Of Singapore N-(2-aminophenyl)-prop-2-enamide derivatives, and uses thereof in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004203749A1 (en) 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers
US8357666B2 (en) 2005-08-01 2013-01-22 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through RNA interference
US20080241110A1 (en) 2005-11-29 2008-10-02 Nevada Cancer Institute Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
AU2006320654A1 (en) 2005-11-29 2007-06-07 Yupo Ma Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
WO2007111733A2 (en) 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
US20090232893A1 (en) 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2009057831A1 (en) 2007-10-31 2009-05-07 Kyoto University Nuclear reprogramming method
WO2009108917A2 (en) 2008-02-29 2009-09-03 Oncomethylome Sciences, S.A. Markers for improved detection of breast cancer

Also Published As

Publication number Publication date
WO2013043128A1 (en) 2013-03-28
SG10201602149XA (en) 2016-04-28
US9365851B2 (en) 2016-06-14
US20150080315A1 (en) 2015-03-19
CN103945860A (en) 2014-07-23

Similar Documents

Publication Publication Date Title
HUS2100012I1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
IL233051A0 (en) Anti-phf-tau-antibodies and their uses
EP2709712A4 (en) Sheath-dilator system and uses thereof
AP4055A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
IL229844B (en) Anti-psgl-1-antibodies and uses thereof
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
GB201110783D0 (en) Methods and uses
SG11201400499PA (en) Sall4 and uses thereof
IL231082A0 (en) Pyrimido - pyridazinone compounds and use thereof
ZA201400406B (en) Trans-clomiphene metabolites and uses thereof
EP2688588A4 (en) Rapid and prolonged immunologic-therapeutic
GB201116774D0 (en) Uses and methods
EP2716359A4 (en) Complex and uses thereof
EP2697386A4 (en) Pepducin design and use
GB201111775D0 (en) Compounds and uses thereof
GB2488408B (en) Insert and degradation assemmbly
EP2693879A4 (en) Migrastatins and uses thereof
HK1203232A1 (en) Biomarker and use thereof
GB201108490D0 (en) Methods and uses
GB201119443D0 (en) GoWinging Concept and patent
PT2734522T (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof
GB201117881D0 (en) Biomarkers and uses thereof